ClinicalTrials.gg
RecruitingNCT07719140LIGHTUpdated Jul 22, 2026

Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

A Phase 4 interventional study of High-dose prednisone and Low-dose prednisone in Childhood-onset Systemic Lupus Erythematosus and Lupus Nephritis (LN), sponsored by Peking Union Medical College Hospital. Recruiting at 8 sites in China. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Planned enrollment
18th of 88
198 · median 51
Started
2026
with 10 others
Phase 4
7 of 96
3 open now
Primary completion
2028-09
later than 37 of 45 live
Registered
93rd of 96
by date
Lead sponsor
3 of 96
Peking Union Medical College Hospital

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 18th largest by planned enrollment of the 88 interventional ones that give a count, is one of 11 that started in 2026, is one of 7 in phase 4, reaches primary completion later than 37 of the 45 other live ones, and was the 93rd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

Childhood-onset systemic lupus erythematosus (cSLE) is a severe chronic autoimmune disease with a high burden of major-organ involvement. Lupus nephritis (LN) affects more than half of children with SLE, and proliferative LN-including class III, IV, III+V, and IV+V disease-is associated with acute kidney injury, progression to end-stage kidney disease, and poor long-term outcomes.

Glucocorticoids remain a cornerstone of induction therapy for proliferative LN. However, the optimal initial dose in children is uncertain. Although recent adult SLE and LN guidelines increasingly recommend lower-dose glucocorticoid regimens with rapid tapering, pediatric guidelines still commonly recommend high initial prednisone doses of 1.5-2.0 mg/kg/day. Adult trials and comparative observational studies suggest that lower-dose glucocorticoid regimens may preserve efficacy while reducing treatment-related toxicity.

Because cumulative glucocorticoid exposure in children may impair growth, development, psychosocial well-being, and medication adherence, this trial will compare low-dose versus high-dose initial glucocorticoid regimens for induction treatment of pediatric proliferative LN. The objective is to determine whether a lower-dose regimen is non-inferior in efficacy while reducing glucocorticoid-related adverse effects and improving quality of life.

03

Conditions studied

  • Childhood-onset Systemic Lupus Erythematosus
  • Lupus Nephritis (LN)

Keywords

  • Children
  • Systemic lupus erythematosus
  • Lupus nephritis
  • Glucocorticoid
  • Therapy
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥6 years and \<18 years, with body weight ≥20 kg
  • Meets the 2019 European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) classification criteria for Systemic Lupus Erythematosus (SLE)
  • Renal confirming Lupus Nephritis class III, IV, III+V, or IV+V according to the International Society of Nephrology / Renal Pathology Society (ISN/RPS) classification
  • At screening: 24-hour urinary protein ≥1.0 g (or ≥25 mg/kg), or urine protein-to-creatinine ratio (UPCR) ≥1.0 g/g
  • White blood cell count ≥3.0 × 10⁹/L and lymphocyte count ≥1.0 × 10⁹/L
  • No prior intravenous methylprednisolone pulse therapy before enrollment, and exposure ≤2 weeks before enrollment, with a maximum prednisone-equivalent dose ≤30 mg/day (or ≤1 mg/kg/day)
  • Written obtained and good treatment compliance expected

Exclusion criteria

Exclusion Criteria:

  • Uncertain diagnosis of SLE, genetically confirmed monogenic lupus, or a history of immunodeficiency
  • Severe infection, including , active , infection, tuberculosis infection, severe fungal infection, etc.
  • Severe neuropsychiatric lupus
  • Peripheral blood \<60 g/L, count \<10 × 10⁹/L, or concomitant aplastic anemia
  • Severe cardiac insufficiency ( functional class ≥ II)
  • Severe pulmonary involvement, including pulmonary hemorrhage, respiratory failure, pulmonary embolism, or other conditions requiring respiratory support
  • Estimated (eGFR) \<60 mL/min/1.73 m²
  • Severe gastrointestinal bleeding, pancreatitis, or hepatic lesions
  • Patients deemed by the investigator to be unsuitable for participation in this trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Active comparator
    Control group (High-dose group)

    Standard high-dose glucocorticoid therapy

    Drug: High-dose prednisone

  • Experimental
    Intervention group (Low-dose group)

    Low-dose glucocorticoid therapy

    Drug: Low-dose prednisone

Interventions

  • DrugPrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will receive two courses of intravenous methylprednisolone pulse therapy (10-30 mg/kg/day for 3 consecutive days per course; maximum 500 mg/day). Participants will then be randomized in a 1:1 ratio to the two treatment groups. In the standard-dose (control) group, oral prednisone will be initiated at 1.4-1.6 mg/kg/day (maximum 60 mg/day), followed by gradual tapering according to the predefined schedule. For participants weighing \<40 kg, doses will be adjusted in proportion to body weight using the following formula: Individual dose = standard dose × body weight (kg) × 0.025. All participants will receive background therapy with oral hydroxychloroquine, mycophenolate mofetil, and intravenous belimumab at standard doses.

  • DrugPrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will receive two courses of intravenous methylprednisolone pulse therapy (10-30 mg/kg/day for 3 consecutive days per course; maximum 500 mg/day). Participants will then be randomized in a 1:1 ratio to the two treatment groups. Participants in the intervention group will receive oral prednisone at an initial dose of 0.6-0.8 mg/kg/day, with a maximum dose of 30 mg/day, followed by gradual tapering according to the predefined schedule. For participants weighing \<40 kg, doses will be adjusted in proportion to body weight using the following formula: Individual dose = standard dose × body weight (kg) × 0.025. The estimated cumulative prednisone dose over 24 weeks will be approximately 50% of that in the control group. All participants will receive background therapy with oral hydroxychloroquine, mycophenolate mofetil, and intravenous belimumab at standard doses.

06

What researchers measure

Primary outcomes

  1. Total Renal Response at Week 24

    Total renal response (TRR) is defined as achievement of complete renal response (CRR), primary efficacy renal response (PERR), or partial renal response (PRR). Complete renal response (CRR) is defined as meeting both of the following criteria: 1. Proteinuria \<0.5 g/1.73 m², or 24-hour urinary protein excretion \<300 mg/m², or urine protein-to-creatinine ratio (UPCR) \<0.5 g/g; and 2. Estimated glomerular filtration rate (eGFR) within the normal range, or eGFR ≥85% of baseline, or a normal serum creatinine level with an increase of no more than 25% from baseline. Primary efficacy renal response (PERR) is defined as meeting both of the following criteria: 1. UPCR \<0.7 g/g; and 2. eGFR ≥80% of baseline or eGFR ≥60 mL/min/1.73 m². Partial renal response (PRR) is defined as meeting both of the following criteria: 1. A ≥50% reduction in proteinuria from baseline and UPCR \<3 g/g; and 2. eGFR ≥85% of baseline.

    Time frame: Week 24

Secondary outcomes

  1. Complete Renal Response at Week 12 and 24

    CRR is defined as meeting both of the following criteria: (1) Urine protein \<0.5 g/1.73 m², or 24-hour urine protein \<300 mg/m², or urine protein-to-creatinine ratio (UPCR) \<0.5 g/g; AND (2) Estimated glomerular filtration rate (eGFR) within the normal range; or eGFR at least 85% of baseline; or normal serum creatinine with an increase of no more than 25% from baseline.

    Time frame: Week 12, 24

  2. Primary Efficacy Renal Response at Week 12 and 24

    PERR is defined as meeting both of the following criteria: (1) UPCR \<0.7 g/g; AND (2) eGFR at least 80% of baseline or eGFR ≥60 mL/min/1.73 m².

    Time frame: Week 12, 24

  3. Partial Renal Response at Week 12 and 24

    PRR is defined as meeting both of the following criteria: (1) Urine protein reduced by ≥50% from baseline and UPCR \<3 g/g; AND (2) eGFR at least 85% of baseline.

    Time frame: Week 12, 24

  4. Time to TRR

    Total renal response (TRR) is defined as achievement of complete renal response (CRR), primary efficacy renal response (PERR), or partial renal response (PRR). Complete renal response (CRR) is defined as meeting both of the following criteria: 1. Proteinuria \<0.5 g/1.73 m², or 24-hour urinary protein excretion \<300 mg/m², or urine protein-to-creatinine ratio (UPCR) \<0.5 g/g; and 2. Estimated glomerular filtration rate (eGFR) within the normal range, or eGFR ≥85% of baseline, or a normal serum creatinine level with an increase of no more than 25% from baseline. Primary efficacy renal response (PERR) is defined as meeting both of the following criteria: 1. UPCR \<0.7 g/g; and 2. eGFR ≥80% of baseline or eGFR ≥60 mL/min/1.73 m². Partial renal response (PRR) is defined as meeting both of the following criteria: 1. A ≥50% reduction in proteinuria from baseline and UPCR \<3 g/g; and 2. eGFR ≥85% of baseline.

    Time frame: Week 0-24

  5. Time to CRR

    Complete renal response (CRR) is defined as meeting both of the following criteria: (1) Urine protein \<0.5 g/1.73 m², or 24-hour urine protein \<300 mg/m², or urine protein-to-creatinine ratio (UPCR) \<0.5 g/g; (2) Estimated glomerular filtration rate (eGFR) within the normal range; or eGFR at least 85% of baseline; or normal serum creatinine with an increase of no more than 25% from baseline.

    Time frame: Week 0-24

  6. Time to PERR

    Primary efficacy renal response (PERR) is defined as meeting both of the following criteria: (1) UPCR \<0.7 g/g; (2) eGFR at least 80% of baseline or eGFR ≥60 mL/min/1.73 m².

    Time frame: Week 0-24

  7. Time to PRR

    Partial renal response (PRR) is defined as meeting both of the following criteria: (1) Urine protein reduced by ≥50% from baseline and UPCR \<3 g/g; (2) eGFR at least 85% of baseline.

    Time frame: Week 0-24

  8. Change of C3 from baseline to Week 24

    To assess the improvement of SLE serum activity

    Time frame: Week 0, 24

  9. Changes of C4 from baseline to Week 24

    To assess the improvement of SLE serum activity

    Time frame: Week 0, 24

  10. Change of anti-dsDNA titer from baseline to Week 24

    To assess the improvement of SLE disease activity

    Time frame: Week 0, 24

  11. Change of anti-dsDNA value from baseline to Week 24

    To assess the improvement of SLE disease activity

    Time frame: Week 0, 24

  12. Change of SLEDAI-2K from baseline to Week 24

    To assess the level of disease activity improvement by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.

    Time frame: Week 0, 24

  13. Change of PGA from baseline to Week 24

    Physician Global Assessment (PGA) is a clinical tool utilizing a 0 to 3 visual analogue scale to measure overall disease activity by experienced rheumatologists.

    Time frame: Week 0, 24

  14. Change of ParentGA from baseline to Week 24

    Parental Global Assessment (ParentGA) is a parent-reported outcome measure used to quantify a caregiver's perception of their child's overall disease impact and well-being. ParentGA consists of a horizontal line containing 21 circles numbered from 0 to 10. The scale moves in 0.5 increments. The score of 0 indicates "very well" (best possible health status/disease activity) and 10 indicates "very poor" (worst possible health status/disease activity).

    Time frame: Week 0, 24

  15. Change of PedsQL from baseline to Week 24

    The Pediatric Quality of Life Inventory (PedsQL) is a modular assessment tool used to measure health-related quality of life in children, evaluating physical, emotional, social, and school functioning to generate an overall health score.

    Time frame: Week 0, 24

  16. Change of serum creatinine from baseline to Week 24

    To measure renal function levels

    Time frame: Week 0, 24

  17. Change of eGFR from baseline to Week 24

    eGFR (estimated Glomerular Filtration Rate) is a calculated value used to assess kidney filtration function. Pediatric eGFR \[mL/(min·1.73m2)\] = K × 88.4 × Height (cm)/Serum Creatinine (μmol/L). When serum creatinine is measured using the Jaffe method, the K coefficient is proportional to an individual's muscle mass and varies with age. In adolescents, it varies according to sex: Children and adolescent females: K = 0.55; Adolescent males: K = 0.77. When creatinine is measured using an enzymatic assay: K = 0.413

    Time frame: Week 0, 24

  18. Change of 24-hour urine protein from baseline to Week 24

    A 24-hour urine protein test measures kidney function by quantifying how much protein the body excretes in a full day.

    Time frame: Week 0, 24

  19. Changes of UPCR from baseline to Week 24

    A UPCR (Urine Protein Creatinine Ratio) test measures the amount of protein relative to creatinine in a single urine sample. It is a highly accurate, convenient alternative to 24-hour urine test.

    Time frame: Week 0, 24

  20. Rate of LN treatment failure at Week 24

    LN treatment failure is defined as the occurrence of any of the following: 1. Death; 2. New-onset end-stage renal disease (ESRD), or the need for dialysis or kidney transplantation; 3. Doubling of serum creatinine (compared with the baseline level); 4. Renal flare, defined by either (a) or (b): 1. Proteinuric flare: after excluding secondary causes such as infection, 24-hour urinary protein excretion or the urine protein-to-creatinine ratio (UPCR) increased to at least twice the baseline level; or 2. Nephritic flare: after excluding secondary causes such as infection, serum creatinine increased by 25% from baseline, together with any of the following: * 24-hour urinary protein increased to at least twice the baseline level and exceeded 2 g/24 h, or the equivalent UPCR; * New-onset hematuria graded as 2+ or more; * New-onset cellular casts.

    Time frame: Week 24

  21. Rate of renal flare at Week 24

    Renal flare, defined by either (a) or (b): 1. Proteinuric flare: after excluding secondary causes such as infection, 24-hour urinary protein excretion or the urine protein-to-creatinine ratio (UPCR) increased to at least twice the baseline level; or 2. Nephritic flare: after excluding secondary causes such as infection, serum creatinine increased by 25% from baseline, together with any of the following: * 24-hour urinary protein increased to at least twice the baseline level and exceeded 2 g/24 h, or the equivalent UPCR; * New-onset hematuria graded as 2+ or more; * New-onset cellular casts.

    Time frame: Week 24

  22. Rate of SLE flare at Week 24

    SLE flare is defined according to SELENA-SLEDAI definitions: 1. An increase in the SLEDAI score of ≥3 points compared with the previous assessment; 2. New-onset or worsening manifestations of lupus activity, including cutaneous lesions, oral or nasal ulcers, pleuritis, pericarditis, arthritis, fever, neuropsychiatric lupus, vasculitis, nephritis, myositis, platelet count \<60 × 10⁹/L, hemolytic anemia (hemoglobin \<70 g/L or a decrease of \>30 g/L), lupus myocarditis, or lupus pneumonitis; 3. Initiation or dose escalation of medications because of disease activity, including NSAIDs, glucocorticoids, cyclophosphamide, methotrexate, or azathioprine; 4. A Physician Global Assessment (PGA; range, 0-3) score of ≥1.

    Time frame: Week 24

  23. Rate of LLDAS at Week 24

    LLDAS was defined as meeting all of the following criteria: 1. SLEDAI-2K score ≤4, with no activity in major organ systems (renal, neuropsychiatric, cardiopulmonary, vasculitic, or constitutional activity), no hemolytic anemia, and no gastrointestinal activity; 2. No new manifestations of SLE disease activity compared with baseline; 3. SELENA-SLEDAI Physician Global Assessment score (range, 0-3) ≤1; 4. Prednisone dose, or equivalent glucocorticoid dose, ≤7.5 mg/day.

    Time frame: Week 24

  24. Rate of DORIS remission at Week 24

    DORIS remission is defined as meeting all of the following criteria: 1. Clinical SLEDAI score = 0; 2. Physician Global Assessment score (range, 0-3) \<0.5, irrespective of serological activity; 3. Treatment with antimalarial agents was permitted, as was prednisone at a dose of ≤5 mg/day (or an equivalent glucocorticoid dose) and/or stable immunosuppressive therapy, including biologic agents.

    Time frame: Week 24

  25. PRINTO/ACR cSLE response rate at Week 24

    Response was defined as improvement of at least 50% from baseline in any two of the five core outcome measures, with no more than one of the remaining measures worsening by more than 30%. The five core outcome measures were Physician Global Assessment of overall disease activity (PGA), Parent Global Assessment of disease activity (ParentGA), proteinuria, the SLE Disease Activity Index 2000 (SLEDAI-2K), and the physical functioning domain of the Pediatric Quality of Life Inventory (PedsQL).

    Time frame: Week 24

  26. Changes of Childhood Lupus Improvement Index (CHILI) from baseline to Week 24

    The Childhood Lupus Improvement Index (CHILI) is a validated measure of treatment response in childhood-onset SLE that primarily captures clinically meaningful improvement. The score is calculated using five core outcome measures: Physician Global Assessment of overall disease activity (PGA), Parent Global Assessment of disease activity (ParentGA), proteinuria assessed by the urine protein-to-creatinine ratio (UPCR) or 24-hour urinary protein excretion, the SLE Disease Activity Index 2000 (SLEDAI-2K), and the physical functioning domain of the Pediatric Quality of Life Inventory (PedsQL). (PMID: 30680946)

    Time frame: Week 0, 24

  27. Rate of clinical, minor, moderate and major improvement in cSLE at Week 24

    Using the CHILI absolute-change definition, clinical improvement is defined as a CHILI score ≥54; minor improvement as CHILI ≥15; moderate improvement as CHILI ≥68; and major improvement as CHILI ≥92.

    Time frame: Week 0, 24

  28. Scores and changes of pGTI from baseline to Week 12 and 24

    The pediatric glucocorticoid toxicity index (pGTI) is a composite index including 10 glucocorticoid toxicity domains: body mass index, growth and development, glucose tolerance, lipid metabolism, systolic blood pressure, bone mineral density, glucocorticoid-induced myopathy, skin toxicity, neuropsychiatric effects, and infection. (PMID: 35917759)

    Time frame: Week 0, 12, 24

  29. SLICC/ACR Damage Index at Week 24

    The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR Damage Index, SDI) is designed to assess cumulative, irreversible organ damage occurring since the onset of SLE. It encompasses 39 types of chronic, irreversible damage across 12 organ systems, irrespective of ongoing inflammatory disease activity. (PMID: 8607884)

    Time frame: Week 24

  30. Category, incidence and severity of adverse events

    Adverse events should be assessed at each study visit, including the event name, timing, management, severity, and outcome. Adverse event grading: Grade 1 (mild): Asymptomatic or mild symptoms; clinical or diagnostic findings only; no treatment required. Grade 2 (moderate): Requires minor or local treatment and limits instrumental activities of daily living. Grade 3 (severe): Medically significant but not immediately life-threatening; hospitalization may be required; limits self-care activities of daily living. Grade 4 (life-threatening): Requires urgent intervention. Grade 5 (death): Death related to the adverse event.

    Time frame: Week 0-24

  31. Change of blood pressure from baseline to Week 24

    To measure improvement of kidney function, and monitor the side effect by glucocorticoids.

    Time frame: Week 0, 24

  32. Change of fasting blood glucose from baseline to Week 24

    To evaluate adverse events of glucocorticoids

    Time frame: Week 0, 24

  33. Changes of serum triglycerides from baseline to Week 24

    To monitor adverse effects of glucocorticoids

    Time frame: Week 0, 24

  34. Changes of height from baseline to Week 24

    To measure the growth velocity of children, and monitor the adverse events of glucocorticoids

    Time frame: Week 0, 24

  35. Changes of bone marrow density from baseline to Week 24

    To monitor the side effects of glucocorticoids, bone mineral density (BMD) is measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine.

    Time frame: Week 0, 24

07

Study locations

2 of 8 sites recruiting
08

References and documents

Publications

  • Wang Y, Li X, Jian S, Li J, Yan J, Sun S, Yang Z, Zheng W, Li Q, Zheng Q, Lu M, Wang M, Yang Q, Mao H, Han T, Lin Y, Zhang Q, Du Y, Tang Y, Cai Y, Sun L, Zhang J, Liu J, Rong Z, Jiang L, Bai H, Chen Y, Yang J, Wang L, Zhang W, Wei X, Zhu Y, Li X, Xie X, Zhou D, Li Y, Cao Y, Shen T, Liu Q, Song H, Wu X; Chinese Alliance of Pediatric Rheumatic and Immunologic Diseases. Mycophenolate Mofetil versus Cyclophosphamide for Initial Therapy in Childhood-Onset Proliferative Lupus Nephritis: A Prospective, Multicenter, Randomized Trial. J Am Soc Nephrol. 2026 Mar 1;37(3):560-568. doi: 10.1681/ASN.0000000866. Epub 2025 Sep 12. PubMed 40938672 ↗
  • Gong Y, Liu S, Liu H, Shi Y, Li Y, Guan W, Zeng Q, Lv Q, Zhang X, Wei Q, Chen J, Shen Q, Xu H, Sun L. Efficacy of initial combination with belimumab in newly diagnosed childhood-onset lupus nephritis: a single-centre historical control study. Lupus Sci Med. 2024 Dec 15;11(2):e001350. doi: 10.1136/lupus-2024-001350. PubMed 39675786 ↗
  • Brogan P, Naden R, Ardoin SP, Cooper JC, De Benedetti F, Dicaire JF, Eleftheriou D, Feldman B, Goldin J, Karol SE, Price-Kuehne F, Skuse D, Stratakis CA, Webb N, Stone JH. The pediatric glucocorticoid toxicity index. Semin Arthritis Rheum. 2022 Oct;56:152068. doi: 10.1016/j.semarthrit.2022.152068. Epub 2022 Jul 14. PubMed 35917759 ↗
  • Brunner HI, Holland MJ, Beresford MW, Ardoin SP, Appenzeller S, Silva CA, Flores F, Goilav B, Avar Aydin PO, Wenderfer SE, Levy DM, Ravelli A, Khubchandani R, Avcin T, Klein-Gitelman MS, Ruperto N, Feldman BM, Ying J; Paediatric Rheumatology International Trial Organisation and Pediatric Rheumatology Collaborative Study Group. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019 May;71(5):579-590. doi: 10.1002/acr.23834. PubMed 30680946 ↗
  • Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22. PubMed 32699034 ↗
  • Brunner HI, Higgins GC, Wiers K, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Klein-Gitelman MS, Giannini EH. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Mar;62(3):335-44. doi: 10.1002/acr.20103. PubMed 20391479 ↗
  • Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999 Feb;37(2):126-39. doi: 10.1097/00005650-199902000-00003. PubMed 10024117 ↗
  • Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, Consolaro A, Magni-Manzoni S, Galasso R, Varnier GC, Martini A, Ravelli A. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010 Jul;37(7):1534-41. doi: 10.3899/jrheum.091474. Epub 2010 Jun 15. PubMed 20551105 ↗
  • Pierrat A, Gravier E, Saunders C, Caira MV, Ait-Djafer Z, Legras B, Mallie JP. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int. 2003 Oct;64(4):1425-36. doi: 10.1046/j.1523-1755.2003.00208.x. PubMed 12969162 ↗
  • Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460. PubMed 22087680 ↗
  • Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E, Radhakrishna SM, Wagner-Weiner L, Adams M, Blier P, Buckley L, Chalom E, Chedeville G, Eichenfield A, Fish N, Henrickson M, Hersh AO, Hollister R, Jones O, Jung L, Levy D, Lopez-Benitez J, McCurdy D, Miettunen PM, Quintero-del Rio AI, Rothman D, Rullo O, Ruth N, Schanberg LE, Silverman E, Singer NG, Soep J, Syed R, Vogler LB, Yalcindag A, Yildirim-Toruner C, Wallace CA, Brunner HI; Carra SLE Subcommittee. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Mar;64(3):375-83. doi: 10.1002/acr.21558. PubMed 22162255 ↗
  • Dall'Era M, Solomons N, Federico R, Truman M. Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies. Lupus. 2019 Apr;28(5):591-596. doi: 10.1177/0961203319842924. PubMed 31066646 ↗
  • Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7. PubMed 33971155 ↗
  • Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9. PubMed 30420324 ↗
  • Subspecialty Group of Renal Diseases, the Society of Pediatrics, Chinese Medical Association. [Evidence-based guideline on diagnosis and treatment of lupus nephritis (2016)]. Zhonghua Er Ke Za Zhi. 2018 Feb 2;56(2):88-94. doi: 10.3760/cma.j.issn.0578-1310.2018.02.003. No abstract available. Chinese. PubMed 29429194 ↗
  • Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-Garcia A, Hiraki LT, Rovin BH, Son MBF, Alvarado A, Aranow C, Barnado A, Broder A, Brunner HI, Chowdhary V, Contreras G, Felix C, Ferucci ED, Gibson KL, Hersh AO, Izmirly PM, Kalunian K, Kamen D, Rollins B, Smith BJ, Thomas A, Timlin H, Wallace DJ, Ward M, Azzam M, Bartels CM, Cunha JS, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Greco J, Cuellar-Gutierrez MC, Iyer P, Johannemann AS, Jorge A, Kasturi S, Kawtharany H, Khawandi J, Kirou KA, Legge A, Liang KV, Lockwood MM, Sanchez-Rodriguez A, Turgunbaev M, Williams JN, Turner AS, Mustafa RA. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol. 2025 Sep;77(9):1115-1135. doi: 10.1002/art.43212. Epub 2025 May 7. PubMed 40331662 ↗
  • Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dorner T, Furie RA, Gladman DD, Houssiau FA, Ines LS, Jayne D, Kouloumas M, Kovacs L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. PubMed 37827694 ↗
  • Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024 Jan;105(1S):S1-S69. doi: 10.1016/j.kint.2023.09.002. No abstract available. PubMed 38182286 ↗
  • Gao S, Yu Z, Ma X, Sun J, Ren A, Gao S, Gong M, Zhou X, Ma M, Song H. Childhood-onset systemic lupus erythematosus in China, 2016-21: a nationwide study. Lancet Child Adolesc Health. 2024 Oct;8(10):762-772. doi: 10.1016/S2352-4642(24)00172-X. PubMed 39299747 ↗

Individual participant data

Plan to share: No — For privacy concerns, individual participant data will not be shared. Summary data will be available with publication and upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Sep 2028, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 22, 2026
StartEst.
Jul 2026
Primary completionEst.
Sep 2028
CompletionEst.
Mar 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719140
Collaborators
Children's Hospital of Chongqing Medical University, Beijing Children's Hospital, Second Xiangya Hospital of Central South University, Shenzhen Children's Hospital, Nanjing Children's Hospital, Jilin University, Children's Hospital of Fudan University
Responsible party
Hongmei Song (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Jul 22, 2026
Start date
Jul 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Sihao Gao, MD, PhD
Contact
sihao.gao@gmail.com
86-10-69155727
Hongmei Song, MD, PhD
principal investigator · Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion